Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
merck
3
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
3
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
bristol-myers squibb
cell therapy
diagnostics
immunotherapy
medicare
new england journal of medicine
nivolumab
novartis
pembrolizumab
pembrolizumab keytruda
What
drug
new
3
×
bio
roundup
advantages
approval
approved
bar
biogen’s
biopharmaceutical
brings
cancer
companies
convo
deeper
dna
earlier
expect
failures
fda
fingerprint
gamble
genetic
going
littered
market
matter
medco’s
medicine
mover
nash
nd
news
oks
patients
payers
physicians
plan
price
pricing
Language
unset
Current search:
merck
×
new
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues